Opinion editor's note: Editorials represent the opinions of the Star Tribune Editorial Board, which operates independently from the newsroom.
•••
"Widely available."
That's how Dr. Ruth Lynfield, Minnesota's respected state epidemiologist, sums up the current supply of antiviral treatments — in other words, pills or outpatient therapies prescribed soon after a positive test for those at risk for severe COVID.
Good news has too often been a rare commodity during this long, exhausting pandemic. But one medication in particular — dubbed Paxlovid — delivers a welcome double shot of that. It's plentiful and potent, being close to 90% effective against hospitalization and death when taken during a limited window of time.
But Paxlovid and other antivirals don't do anyone any good if they're gathering dust on a clinic or pharmacy shelf. While these may have been in short supply temporarily after they were cleared for use in the United States — Paxlovid's emergency authorization for those ages 12 and up came in December, for example — there's now a healthy inventory of them here and elsewhere.
Other treatments include remdesivir, bebtelovimab and molnupiravir. The first two are given as outpatient infusions; the last is taken by mouth. The age range and other eligibility criteria varies from treatment to treatment. The issue now is ensuring that Minnesotans are not only aware of these options, but understand who should use them and when.
The list of conditions that elevate risk for severe COVID is likely more expansive than many realize. It includes older adults, particularly those 65 and over. Also on the list: Type 1 and 2 diabetes, chronic lung conditions such as asthma, as well as heart, liver and kidney disease. Mood disorders, including depression, and schizophrenia spectrum disorders, are risk factors as well. A full list is available from the U.S. Centers for Disease Control and Prevention at tinyurl.com/Risk042522, but when in doubt ask a doctor or pharmacist.